June 9, 2022 -- Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in non-viral DNA-delivered gene therapy, according to Xalud Therapeutics CEO Diem Nguyen, PhD.
"As we move toward the industry evolution, we're learning that there are some challenges associated with viral gene therapy and we've moved to, I think, based on the pandemic, a huge welcoming of mRNA and it's obvious from the vaccine perspective," Nguyen told ScienceBoard.net. "Certainly, from that continuum, you can imagine a benefit associated, not only with mRNA, but I would call nucleic acid delivery and specifically for our company we focus on DNA delivery."
Nguyen, whose biotech company is developing a novel DNA-delivered gene therapy platform to treat pathologic inflammation through immune modulation, will be a panelist in two separate panels on June 14 and June 15 at the 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego.
The June 15 BIO panel, "A New Era in Gene Therapy," will address accessibility concerns ranging from drug development efficacy to safe therapeutic vectors and how to improve manufacturing to broaden the application of gene therapy to challenging diseases.
Watch the video below to learn more.